Shares in Caravel Minerals Ltd (ASX: CVV) have improved more than 39% over the past year, but they’re still trading well off their highs over the period.

But the analyst team at Shaw and Partners has recently initiated coverage on the ASX copper stock and believes shareholders should persist, predicting serious share price upside for the company.

Major copper project in development

So what does Caravel do? The company is currently finalising the definitive feasibility study for its Caravel copper project 150km northeast of Perth.

Shaw and Partners said in its recent research report that Caravel was one of the largest undeveloped copper resources globally.

They added:

The project is a large-scale, low-cost operation that will utilise bulk mining and automation to drive strong unit cost efficiencies, supported by its proximity to Perth, only 150km away. With a Tier-1 resource, progressing permitting and emerging strategic funding interest, Caravel is well positioned to develop a globally significant copper operation leveraged to ongoing structural demand growth from electrification, EVs and AI.

Shaw and Partners said a key advantage for the project was its proximity to established infrastructure which was unusual for projects of this size.

They added:

Located within trucking distance of Perth and connected to existing sealed roads, power infrastructure and skilled labour pools, the project avoids many of the logistical challenges faced by more remote copper developments. This infrastructure access significantly lowers capital intensity and operating risk relative to comparable greenfield projects.

Shaw and Partners said Caravel was progressing funding options while the definitive feasibility study was being finalised, “with the project’s scale and long mine life lending itself to a diversified capital stack”.

They added:

Caravel will pursue a mix of project debt, strategic investment and potential offtake-linked financing, to minimise dilution while providing the balance sheet required for construction. Strong interest from potential strategic partners and lenders, highlighted by the Adani non-binding MoU, reflects growing global demand for secure copper supply. This positioning enables Caravel to assemble a robust funding structure as development decisions approach.

Shaw and Partners said the growing demand for copper supported the reasons to buy ito the stock.

They said rapid growth in renewable energy, the electrification of transport and, “the rising power intensity of AI-driven data centres are expected to drive sustained copper consumption over the short, medium and long-term”.

The project also had significant precious metal and molybdenum by-products, Shaw and Partners said.

The broker has a $1.15 share price target on Caravel shares, which would be a 400% gain from the current share price of 23 cents.

Caravel is valued at $128.5 million.

The post Could this ASX copper share really rise 400%? appeared first on The Motley Fool Australia.

More reading

• This ASX silver mine developer could more than triple in value: Broker
• Mesoblast shares: Q4 earnings top projections
• Australia may sign a nuclear deal with India this week. What does that mean for Boss Energy shares?
• Ingenia Communities Group shares paused pending announcement
• Which is the best buy, Coles shares or Wesfarmers shares?

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The Mesoblast Ltd (ASX: MSB) share price is in focus today after the company reported fourth-quarter net revenue of US$36 million, boosting full-year revenue to US$115 million for the period ended 30 June 2026.

What did Mesoblast report?

• Fourth quarter net revenue: US$36 million
• Full-year net revenue: US$115 million
• Ryoncil^® uptake exceeded initial projections
• Strong capital position and funding for operations

What else do investors need to know?

Ryoncil^® is the first mesenchymal stromal cell (MSC) product approved by the US FDA for any indication and remains the only FDA-approved option for children under 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD). This achievement has positioned Mesoblast as a leading developer of allogeneic cellular medicines targeting severe inflammatory diseases.

The company’s manufacturing capabilities continue to deliver industrial-scale, off-the-shelf cellular medicines. Mesoblast also has an extensive intellectual property portfolio, with patents that provide commercial protection through to at least 2044 in key markets.

What’s next for Mesoblast?

Looking ahead, Mesoblast expects continued revenue growth, supported by momentum across major US paediatric centres. The company’s robust capital base and new five-year facility are intended to support further strategic initiatives, including label extensions and new blockbuster product launches.

Mesoblast is advancing its Ryoncil^® therapy for additional inflammatory diseases, such as SR-aGvHD in adults and biologic-resistant inflammatory bowel disease, while its rexlemestrocel-L platform targets heart failure and chronic low back pain.

Mesoblast share price snapshot

Over the past 12 months, Mesoblast shares have risen 27%, outperforming the S&P/ASX 200 Index (ASX: XJO), which has risen 2% over the same period.

View Original Announcement

The post Mesoblast shares: Q4 earnings top projections appeared first on The Motley Fool Australia.

More reading

• Ingenia Communities Group shares paused pending announcement
• Why brokers think Zip shares could soar 50% or more in FY27
• NEXTDC boosts funding with $2.3 billion senior debt facility upsize
• ASX 200 shares vs. US stocks in FY26
• 5 things to watch on the ASX 200 on Friday

Motley Fool contributor Laura Stewart has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips. This article was prepared with the assistance of Large Language Model (LLM) tools for the initial summary of the company announcement. Any content assisted by AI is subject to our robust human-in-the-loop quality control framework, involving thorough review, substantial editing, and fact-checking by our experienced writers and editors holding appropriate credentials. The Motley Fool Australia stands behind the work of our editorial team and takes ultimate responsibility for the content published by The Motley Fool Australia.

Boss Energy Ltd (ASX: BOE) shares have had a difficult year.

After a savage 43.8% single-day fall in July 2025 following a production guidance cut at its Honeymoon uranium mine in South Australia, the stock has struggled to recover, sitting approximately 20% lower year to date.

This week, however, a significant catalyst has emerged that the market is watching closely.

There are reports that the Australian Government could sign an agreement with India this week that delivers on a nuclear co-operation plan between the two countries.

If confirmed, the agreement would open the door for Australia to export uranium directly to India. One of the world’s fastest-growing nuclear markets.

Why India could be a big buyer of uranium

India’s nuclear ambition is not speculative.

RBC Capital Markets noted in a recent report that India has committed to growing its nuclear capacity tenfold by 2047. This is one of the most significant long-term demand commitments any country has made to nuclear energy.

India currently generates approximately 3% of its electricity from nuclear power, compared to 70% in France and 19% in the United States.

Reaching its 2047 target would require an extraordinary buildout of reactor capacity over the next two decades and a corresponding, sustained surge in uranium demand.

Australia holds more than one-third of the world’s known uranium reserves, making it the largest reserve holder on the planet.

However, Australia has historically been unable to supply uranium directly to India because the two countries lacked the bilateral safeguards agreement required under Australia’s strict uranium export policy.

That is what the agreement being reported this week would change.

What it means for Boss Energy shares

Boss Energy surged 12.2% in a single session on 3 July after meeting its revised FY26 production guidance of 1.41 million pounds of uranium at its Honeymoon project.

That bounce confirmed the market is still willing to respond positively to strong operational news.

A confirmed nuclear deal with India would be a far more significant catalyst than a production update. This is because it would open a new, large export market for Australian uranium producers at a time when global uranium demand is already strengthening.

Shaw and Partners carries a buy rating on Boss Energy with a price target of $3.15, implying significant upside. These ratings were based on an upgraded uranium price forecast that sees the fuel reaching US$175 per pound in 2027.

The broker described the uranium market backdrop as one where:

Energy security, decarbonisation and AI-driven power demand are converging. Nuclear is no longer a fringe solution. It is becoming central to energy policy.

The risks investors need to understand

Boss Energy is not a risk-free investment, and the India deal has not yet been confirmed.

The Honeymoon project has had a difficult operational history, with production guidance cut twice in FY26 and a new feasibility study still in progress.

A new feasibility study is targeting completion in Q3 calendar year 2026, which will determine the long-term production outlook for the mine.

Until that study is complete, there is uncertainty about what Honeymoon can produce at scale, and at what cost.

Furthermore, uranium spot prices remain volatile, and the India deal, even if signed, would take time to translate into actual contracts and physical uranium deliveries.

Foolish Takeaway for Boss Energy shares

Boss Energy shares are down in 2026 on the back of a difficult operational year.

A nuclear co-operation agreement with India, if signed this week, would be the most significant demand-side catalyst the Australian uranium sector has received in years.

Whether that translates into a sustained recovery for Boss Energy depends partly on the Honeymoon feasibility study delivering a credible long-term production case.

Investors should watch both developments closely in the weeks ahead.

The post Australia may sign a nuclear deal with India this week. What does that mean for Boss Energy shares? appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Thursday
• These are the 10 most shorted ASX shares
• Boss Energy shares surging 12% today on big uranium news
• 6 ASX shares upgraded by experts this week
• Why are these 2 ASX uranium stocks shooting higher today?

Motley Fool contributor Mark Verhoeven has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.